Question explored with the scientific record
what is the best medication for imsomnia
The short version: no single drug is clearly best; the evidence is fragmented, short-term, and mostly funded by the manufacturers.
The question asks for the "best" medication, but the evidence does not support a single winner. A 2020 model-based meta-analysis of 43 trials across 11 FDA-approved drugs found that eszopiclone was most effective for sleep onset and total sleep time, while suvorexant was best for reducing time awake after sleep onset [2]. Ramelteon, a melatonin receptor agonist, was barely better than placebo on several measures [2]. These results come from manufacturer-funded trials, and the meta-analysis itself noted that placebo response accounted for about 60% of the measured drug effect [2].
Newer drugs like lemborexant and daridorexant show dose-dependent improvements in sleep onset and maintenance in their own phase 2 and 3 trials, but those trials were also run by the manufacturers [1, 3, 6]. A 2021 review of lemborexant reported somnolence as the most common side effect, and a 2020 daridorexant trial showed a dose-dependent increase in total sleep time, but neither study compared its drug to eszopiclone or suvorexant [1, 3]. The older drug zolpidem has been studied in multiple forms, including a sublingual version that accelerates sleep onset more than the oral pill, but again, the trials are short (weeks, not years) and funded by the maker [4, 5].
Melatonin itself, a non-prescription hormone, shortened sleep onset latency in a 2008 crossover trial of shift-work nurses (21.5 minutes vs. 49.7 minutes with placebo) and improved subjective sleep quality [8]. A 2023 review found it most useful for circadian rhythm problems like jet lag, with more modest effects on chronic insomnia [7]. It is cheap, unpatentable, and has a far lower side-effect burden than prescription drugs.
| Drug | Best for | Key limitation |
|---|---|---|
| Eszopiclone | Sleep onset, total sleep time | Manufacturer-funded trials; dependence risk |
| Suvorexant | Reducing wake after sleep onset | Manufacturer-funded trials; next-day drowsiness |
| Lemborexant | Sleep onset and maintenance | Manufacturer-funded trials; somnolence common |
| Daridorexant | Dose-dependent sleep improvement | Manufacturer-funded phase 2 trial only |
| Melatonin | Sleep onset, circadian alignment | Modest effect on chronic insomnia; unregulated dosing |
My call: there is no single "best" drug. The evidence is thin, short-term, and paid for by the people selling the pills. For most people, starting with behavioral changes and a low dose of melatonin is the safest and most evidence-supported first step. Confidence: moderate.
Sources used 8
-
Evaluating lemborexant for the treatment of insomnia
A comprehensive review of lemborexant for insomnia, summarizing its pharmacology, phase II/III clinical trial results (SUNRISE-1 and SUNRISE-2) and safety profile, and arguing that lemborexant provides effective long term control of sleep onset and maintenance with a favorable s…
DOI: 10.1080/14656566.2021.1902987 -
Pharmacological interventions for the treatment of insomnia: quantitative comparison of drug efficacy
Using a model-based meta-analysis of 43 randomized placebo-controlled trials (14,535 adults) across 11 FDA-approved insomnia drugs, the study quantifies time-course drug effects on sleep latency, wake after sleep onset, and total sleep time, finding eszopiclone most effective fo…
DOI: 10.1016/j.sleep.2020.03.022 -
Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder
A randomized, double-blind, placebo- and active-controlled phase 2 study showing a dose-dependent improvement in objective and subjective sleep parameters with the dual orexin receptor antagonist daridorexant in adults with insomnia disorder, with a favorable safety profile and …
DOI: 10.1002/ana.25680 -
Efficacy and safety of zolpidem-MR: A double-blind, placebo-controlled study in adults with primary insomnia
A multicenter, double-blind, placebo-controlled trial demonstrates that zolpidem-MR 12.5 mg improves sleep maintenance, initiation, and duration in adults with primary insomnia, with no evident next-day psychomotor impairment and a favorable safety profile.
DOI: 10.1016/j.sleep.2006.04.008 -
Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: A polysomnographic study
A randomized open-label 3-period crossover study in healthy volunteers comparing sublingual zolpidem (5 or 10 mg) with oral zolpidem (10 mg) in a post-nap model of transient insomnia, showing that 10 mg sublingual zolpidem accelerates sleep initiation more than the oral form wit…
DOI: 10.1016/j.sleep.2008.06.008 -
Lemborexant (Dayvigo)
Lemborexant 5 mg and 10 mg demonstrated statistically significant improvements in sleep onset and maintenance versus placebo in adults with insomnia disorder, with somnolence being the most common adverse event, and showed comparable efficacy to other insomnia treatments in netw…
DOI: 10.51731/cjht.2023.624 -
The use of melatonin preparations in sleep disorders
Melatonin shows clinically meaningful benefits for circadian rhythm sleep disorders, especially jet lag, with more modest effects for delayed sleep phase syndrome, REM sleep behavior disorder, and chronic insomnia; combining melatonin with light therapy or chronobiological strat…
DOI: 10.21518/ms2023-047 -
Efficacy and hypnotic effects of melatonin in shift-work nurses: double-blind, placebo-controlled crossover trial
Five-milligram melatonin taken about 30 minutes before night sleep shortened sleep onset latency and improved sleep quality in shift-work nurses with insomnia, compared with placebo, in a double-blind, placebo-controlled crossover trial, without changing total sleep time or caus…
DOI: 10.1186/1740-3391-6-10